Literature DB >> 10869852

Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons.

P Honore1, S D Rogers, M J Schwei, J L Salak-Johnson, N M Luger, M C Sabino, D R Clohisy, P W Mantyh.   

Abstract

The aim of this investigation was to determine whether murine models of inflammatory, neuropathic and cancer pain are each characterized by a unique set of neurochemical changes in the spinal cord and sensory neurons. All models were generated in C3H/HeJ mice and hyperalgesia and allodynia behaviorally characterized. A variety of neurochemical markers that have been implicated in the generation and maintenance of chronic pain were then examined in spinal cord and primary afferent neurons.Three days after injection of complete Freund's adjuvant into the hindpaw (a model of persistent inflammatory pain) increases in substance P, calcitonin gene-related peptide, protein kinase C gamma, and substance P receptor were observed in the spinal cord. Following sciatic nerve transection or L5 spinal nerve ligation (a model of persistent neuropathic pain) significant decreases in substance P and calcitonin gene-related peptide and increases in galanin and neuropeptide Y were observed in both primary afferent neurons and the spinal cord. In contrast, in a model of cancer pain induced by injection of osteolytic sarcoma cells into the femur, there were no detectable changes in any of these markers in either primary afferent neurons or the spinal cord. However, in this cancer-pain model, changes including massive astrocyte hypertrophy without neuronal loss, increase in the neuronal expression of c-Fos, and increase in the number of dynorphin-immunoreactive neurons were observed in the spinal cord, ipsilateral to the limb with cancer. These results indicate that a unique set of neurochemical changes occur with inflammatory, neuropathic and cancer pain in C3H/HeJ mice and further suggest that cancer induces a unique persistent pain state. Determining whether these neurochemical changes are involved in the generation and maintenance of each type of persistent pain may provide insight into the mechanisms that underlie each of these pain states.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869852     DOI: 10.1016/s0306-4522(00)00110-x

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  152 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

Review 2.  UDP facilitates microglial phagocytosis through P2Y6 receptors.

Authors:  Kazuhide Inoue
Journal:  Cell Adh Migr       Date:  2007-07-27       Impact factor: 3.405

3.  Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain.

Authors:  Hai-Li Pan; Ben-Long Liu; Wei Lin; Yu-Qiu Zhang
Journal:  Neurosci Bull       Date:  2016-09-09       Impact factor: 5.203

Review 4.  Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain.

Authors:  Gang Chen; Yu-Qiu Zhang; Yawar J Qadri; Charles N Serhan; Ru-Rong Ji
Journal:  Neuron       Date:  2018-12-19       Impact factor: 17.173

5.  Chapter 9 The dorsal horn and hyperalgesia.

Authors:  Karin N Westlund
Journal:  Handb Clin Neurol       Date:  2006

6.  Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway.

Authors:  Ru-Rong Ji; Yasuhiko Kawasaki; Zhi-Ye Zhuang; Yeong-Ray Wen; Isabelle Decosterd
Journal:  Neuron Glia Biol       Date:  2006-11

7.  Etanercept attenuates thermal and mechanical hyperalgesia induced by bone cancer.

Authors:  Yan Yang; Juan Zhang; Qin Gao; Jinhua Bo; Zhengliang Ma
Journal:  Exp Ther Med       Date:  2017-03-23       Impact factor: 2.447

8.  Thrombospondin-4 and excitatory synaptogenesis promote spinal sensitization after painful mechanical joint injury.

Authors:  Nathan D Crosby; Frank Zaucke; Jeffrey V Kras; Ling Dong; Z David Luo; Beth A Winkelstein
Journal:  Exp Neurol       Date:  2014-12-05       Impact factor: 5.330

Review 9.  Mechanisms that drive bone pain across the lifespan.

Authors:  Patrick W Mantyh
Journal:  Br J Clin Pharmacol       Date:  2018-11-22       Impact factor: 4.335

10.  Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model.

Authors:  Yong-Jing Gao; Jen-Kun Cheng; Qing Zeng; Zhen-Zhong Xu; Isabelle Decosterd; Xiaoyin Xu; Ru-Rong Ji
Journal:  Exp Neurol       Date:  2009-05-13       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.